Related Experiment Video
Updated: Jun 13, 2026
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Valproic acid enhances microglial phagocytosis of amyloid-beta(1-42)
A M Smith1, H M Gibbons, M Dragunow
1Department of Pharmacology, Faculty of Medical and Health Sciences and the National Research Centre for Growth and Development, The University of Auckland, Auckland, New Zealand.
Abstract:
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder manifested by memory loss, confusion and changes in mood. A principal pathology of this debilitating disorder is extracellular deposits of amyloid-beta (Abeta) protein. The "amyloid hypothesis" postulates that a build-up of Abeta protein is responsible for neuronal loss and the ensuing symptoms of AD. One possible mechanism of Abeta clearance, and hence AD therapy, is phagocytosis of Abeta protein by microglial cells. Microglia are the brain's resident immune cells and phagocytosis is one of their innate functions. We are interested in identifying molecules that augment microglial-mediated phagocytosis of Abeta protein. We used the rodent BV-2 microglial cell line which readily phagocytose fluorescent latex beads and synthetic Abeta(1-42) peptide. BV-2 cells treated with the neuroactive drug valproic acid (VPA) showed greatly enhanced phagocytic activity for both latex beads and Abeta. VPA also reduced microglial viability by inducing apoptosis, as previously reported. The relevance of these in vitro results to the treatment of AD is unclear but further investigation into the effects of VPA on the clearance of Abeta through enhanced microglial phagocytosis is warranted.
Insights
Valproic acid (VPA) enhances microglial phagocytosis of amyloid-beta (Abeta), a key protein implicated in Alzheimer's disease (AD). Further research is needed to explore VPA's therapeutic potential for AD by improving Abeta clearance.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and confusion.
- Extracellular amyloid-beta (Abeta) deposits are a primary pathology in AD.
- Microglial cells, the brain's immune cells, clear Abeta through phagocytosis, offering a potential therapeutic target.
Purpose of the Study:
- To identify molecules that enhance microglial phagocytosis of Abeta.
- To investigate the effect of valproic acid (VPA) on microglial phagocytic activity.
Main Methods:
- Utilized the rodent BV-2 microglial cell line.
- Assessed phagocytosis of fluorescent latex beads and synthetic Abeta(1-42) peptide.
- Treated BV-2 cells with valproic acid (VPA) and measured phagocytic activity and cell viability.
Main Results:
- Valproic acid (VPA) significantly enhanced the phagocytic activity of BV-2 microglial cells for both latex beads and Abeta.
- VPA treatment also induced apoptosis, reducing microglial viability, consistent with previous findings.
Conclusions:
- Valproic acid (VPA) demonstrates potential in augmenting microglial-mediated clearance of amyloid-beta (Abeta).
- Further investigation is warranted to explore the in vitro findings' relevance to Alzheimer's disease (AD) treatment.
- The study highlights the need for more research into VPA's effects on Abeta clearance via enhanced microglial phagocytosis.
